What We're Reading: Page 320
Industry reads hand-picked by our editors
Jul 07, 2016
Jul 06, 2016
-
Wall Street Journal
Valeant's new CEO brings familiar prescription
-
Stat
In clinical trials, for-profit review boards are taking over for hospitals. Should they?
-
Reuters
EU rivals vie to wrest drug and banking agencies from London
-
New York Times
California drug price plan is criticized by patient advocates
Jul 05, 2016
Jul 01, 2016
-
Endpoints
Where the money is: Biotech’s megahubs command VC’s billions
-
Wall Street Journal
Brexit Could Boost Drug Costs for Britain’s National Health Service
-
Reuters
UK drugs regulator halts approvals for Indian clinical trials firm
-
FiercePharma
Arena chops 100-plus jobs as it shifts its priorities from struggling Belviq
Jun 30, 2016
-
Forbes
Top Officials Aim To Reshape The FDA To Prepare For 'Avalanche' Of Cancer Products
-
Stat
New ovarian cancer drugs raise hope — but not for all
-
Bloomberg
This Gene-Editing Technology Will Change the World. But Who Gets the Credit?
-
Boston Business Journal
Cambridge diagnostic firm to double size of 'Moonshot' cancer database
Jun 29, 2016
-
Reuters
FDA names Pazdur head of new Oncology Center of Excellence
-
Bloomberg
Allergan Seeks Smaller M&A for Growth After Pfizer Breakup
-
The Street
Esperion Falls on Regulatory Setback for Cholesterol-Lowering Pill
-
PM Live
inVentiv Health wins Pfizer account
-
HR Dive
Creating a 'culture of data': How HR can use analytics in a meaningful way
Jun 28, 2016
-
Boston Business Journal
Why Sarepta just made its soon-to-begin drug trial even longer
-
Stat
The Supreme Court decision that’s shaking up biotech
-
Xconomy
After Failed Schizophrenia Trial, Forum Pharma To Shutter This Week
-
The Pharma Letter
Roche’s Ocrevus for two forms of MS accepted for review by EMA and FDA
Previous
